期刊
CURRENT CANCER DRUG TARGETS
卷 16, 期 4, 页码 357-372出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568009616666151106120606
关键词
MCF-7 breast cancer cell lines; phosphoethanolamine-conjugated nanoliposome; sustained manner; tamoxifen citrate
类别
资金
- Indian Council of Medical Research [45/16/2011-NAN/BMS]
Among the various drug delivery devices, nanoliposome is an emerging formulation in the treatment of cancer. Here we have developed tamoxifen citrate (TC) loaded nanoliposome conjugated with phosphoethanolamine (PE) by thin film hydration method. Various physicochemical and biopharmaceutical characterization studies such as drug-excipients interaction, surface morphology, energy dispersive X-ray analysis, zeta potential, in vitro drug release, cellular uptake, in vitro cytotoxicity assay and in vivo pharmacokinetic profiles were conducted. TC-loaded nanoliposome (TNL1) and PE-conjugated TC-loaded nanoliposome (TNL-PE) showed 3.23 +/- 0.26% and 3.07 +/- 0.05% drug loading values, respectively. Average diameters (z-average) of the nanoliposomes were within 100 nm, with negative zeta potentials and cumulative percentages of drug release were 75.77 +/- 12.21% and 61.04 +/- 10.53% at 30 h for TNL1 and TNL-PE respectively. Predominant uptake of both the types of nanoliposomes was visualized in MCF-7 breast cancer cells. TNL1 and TNL-PE decreased the cell viability from 95.95 +/- 0.37 to 12.22 +/- 0.64% and from 96.51 +/- 0.24 to 13.49 +/- 0.08% respectively. In vivo pharmacokinetic study showed that AUC(0-infinity), AUMC(0-infinity), MRT, and t(1/2) value of TNL-PE increased (22%, 100%, 2.66 fold and 60% respectively) as compared to the free drug. Administration of TNL-PE decreased the renal clearance value (about 38%) as compared to the free drug. TNL1 and TNL-PE released the drug in a sustained manner. Further, TNL-PE may be used for active targeting for breast cancer cells when it is tagged with specific antibodies to PE, a linker molecule.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据